Tests atorvastatin after childbirth in people who had high blood pressure in pregnancy
Tests atorvastatin against placebo in people with pregnancy-related high blood pressure after childbirth.
Plain-language title generated from the registry record
Registry title: AtorvaStatin Postpartum and Reduction of Cardiovascular risK
Key facts
- Where
- Columbus, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 50 years old?
Source: NCT06632379, who can take part
Where in United States
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal MedicineColumbus, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ohio State University
- Trial code
- NCT06632379
- Record updated
- 23 October 2026
- Original description
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.Read full original descriptionShow less
AtorvaStatin Postpartum and Reduction of Cardiovascular risK (SPARK): A Randomized Placebo-controlled Trial of Atorvastatin Postpartum for Reduction of Cardiovascular Risk
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.
Inclusion: Postpartum; ≥ 20 years old with the ability to give informed consent; Diagnosis of gestational hypertension, preeclampsia prior to delivery admission, or diagnosed with preeclampsia during delivery admission, as determined by clinical team using the American College of Obstetricians and Gynecologists (ACOG) criteria; English speaking.
Exclusion: Individuals who were prescribed an 3-hydroxy-3 methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor prior to or during pregnancy,; Known familial hypercholesterolemia or pre-existing hyperlipidemia, specifically Low-density Lipoprotein (LDL) >190 prior to pregnancy or diagnosis of hyperlipidemia with prescription of HMG-CoA reductase inhibitor prior to delivery,; Hypertensive diagnosis thought to be secondary to fetal condition,; Contraindications to HMG-CoA reductase inhibitor therapy or known hypersensitivity to atorvastatin or any component,; History of rhabdomyolysis or myopathy,; Human Immunodeficiency Virus (HIV) positivity, due to potential interactions between atorvastatin and HIV protease inhibitors,; History of solid organ transplant, due to potential interactions between atorvastatin and immunosuppressants; Active cancer, or; Current use of medications with potential drug interactions, namely cyclosporine, clarithromycin, itraconazole, HIV protease inhibitors, rifampin, and digoxin; Active liver disease (acute hepatitis, chronic active hepatitis, unexplained persistent transaminitis (at least twice upper limit of normal serum transaminases)),; Breastfeeding for >= 6 months,; Plan for pregnancy conception in the next 6 months,; Incarcerated individuals,.